Advertisement
Organisation › Details
Santhera (Group)
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of severe neuromuscular and neurodegenerative diseases, an area of high unmet medical need which includes many orphan and niche indications with no current therapy. Santhera's first product, Catena® to treat Friedreich's Ataxia is marketed in Canada. *
Start | 2004-09-08 merged | |
Today | Santhera Pharmaceuticals AG | |
Predecessor | Graffinity Pharmaceuticals AG | |
Industry | BIOTECH | |
Person | Meier, Thomas (Viopas Venture Consulting 202201 Managing Partner before Santhera Pharmaceuticals) | |
Region | Liestal BL | |
Country | Switzerland | |
Street | 24 Hohenrainstr. | |
City | 4133 Pratteln | |
Tel | +41-61-906-8950 | |
Address record changed: 2023-11-02 | ||
Basic data | Employees | D: 101 to 500 (2017-12-31) |
Currency | CHF | |
Annual sales | 22,943,000 (sales, net, consolidated (2017) 2017-12-31) | |
Profit | -51,532,000 (2017-12-31) | |
Cash | 45,195,000 (2017-12-31) | |
* Document for »About Section«: | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Santhera (Group)
- [1] Santhera Pharmaceuticals Holding AG. (10/27/23). "Press Release: Santhera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy [Ad hoc announcement pursuant to Art. 53 LR]". Pratteln....
- [2] Santhera Pharmaceuticals Holding AG. (6/20/23). "Press Release: Santhera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties [Ad hoc announcement pursuant to Art. 53 LR]...
- [3] Santhera Pharmaceuticals Holding AG. (1/4/22). "Press Release: Santhera Enters into Exclusive License Agreement with Sperogenix for Vamorolone in Rare Diseases in the Greater China Region". Pratteln....
- [4] Santhera Pharmaceuticals Holding AG. (11/4/21). "Press Release: Santhera Appoints Stephanie Brown as President North America and Member of the Executive Management Team". Pratteln....
- [5] Santhera Pharmaceuticals Holding AG. (10/6/20). "Press Release: Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa in Duchenne Muscular Dystrophy (DMD) and Focus on Vamorolone". Pratteln....
- [6] Santhera Pharmaceuticals Holding AG. (1/24/20). "Press Release: Santhera Appoints New Chief Financial Officer". Pratteln....
- [7] Santhera Pharmaceuticals AG. (11/4/19). "Press Release: Santhera Appoints New Chief Executive Officer". Pratteln....
- [8] Santhera Pharmaceuticals Holding AG. (12/14/18). "Press Release: Santhera Raises Gross Proceeds of CHF 23.5 Million and Secures Acquisition of Option to Vamorolone Sub-license". Pratteln....
- [9] Santhera Pharmaceuticals Holding AG. (12/12/18). "Press Release: Santhera Announces Financial Results for the First Nine Months of 2018". Pratteln....
- [10] Santhera Pharmaceuticals Holding AG. (11/21/18). "Press Release: Santhera Enters into Agreement to Acquire Option from Idorsia for Exclusive Sub-License of First-in-class Dissociative Steroid Vamorolone". Pratteln & Allschwil....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top